Trials / Unknown
UnknownNCT04155879
Atrial Fibrillation Recurrence Following Cardioversion: the Role of Clinical Factors and Alpha Defensin Levels
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Atrial fibrillation and inflammation are strongly correlated. The aim of this study is to evaluate whether inflammation markers (alpha Defensin) predict maintenance of sinus rhythm following cardioversion. A secondary aim is to evaluate the role of Colchicine, an anti-inflammatory medication, in reducing the recurrence rate of atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine Tablets | Administration of Colchicine at a dose of 0.5mg 2x a day for six months. |
| PROCEDURE | Cardioversion | Electrical or pharmacologic restoration of sinus rhythm |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2019-11-07
- Last updated
- 2019-11-07
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04155879. Inclusion in this directory is not an endorsement.